Literature DB >> 6366129

Philadelphia chromosome and terminal transferase-positive acute leukemia: similarity of terminal phase of chronic myelogenous leukemia and de novo acute presentation.

K Jain, Z Arlin, R Mertelsmann, T Gee, S Kempin, B Koziner, A Middleton, S Jhanwar, R Chaganti, B Clarkson.   

Abstract

Twenty-eight patients with Philadelphia chromosome (Ph1)--positive and terminal transferase (TdT)--positive acute leukemia (AL) were treated with intensive chemotherapy used for adult acute lymphoblastic leukemia (L-10 and L-10M protocols). Fifteen patients had a documented chronic phase of Ph1-positive chronic myelogenous leukemia preceding the acute transformation (TdT + BLCML) while the remaining 13 patients did not (TdT + Ph1 + AL). An overall complete remission (CR) rate of 71% was obtained with a median survival of 13 months in the responders. Clinical presentation, laboratory data, cytogenetics, response to treatment, and survivals of the two groups of patients are compared. These results appear to be similar, suggesting a common or closely related origin. Since the overall survival of those receiving chemotherapy maintenance is poor, three patients underwent allogeneic bone marrow transplantation (BMT) from histocompatibility leukocyte antigen--matched siblings after they achieved CR. One of them is a long-term survivor (35 + months) with a Ph1-negative bone marrow. New techniques such as BMT should be considered in young patients with a histocompatibility leukocyte antigen--compatible sibling once a CR has been achieved.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6366129     DOI: 10.1200/JCO.1983.1.11.669

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  2 in total

1.  Study of Haploidentical Stem Cell Transplantation for Philadelphia/BCR-ABL Positive Acute Lymphoblstic Leukemia.

Authors:  Narendra Agrawal; Neha Yadav; Priyanka Verma; Priyanka Soni; Pallavi Mehta; Shinto Francis Thekkudan; Rayaz Ahmed; Dinesh Bhurani
Journal:  Indian J Hematol Blood Transfus       Date:  2019-02-13       Impact factor: 0.900

2.  Treatment of blastic transformation of chronic myelogenous leukemia with mitoxantrone.

Authors:  Z A Arlin; E Berman; S Jhanwar; R Gams; I Schoch; G Dukart
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.